VRDN - Company ID 0001590750
The table below shows Viridian Therapeutics, Inc.DE's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$119.65M | -$92.65M | -$45.22M | -$61.97M | -$21.04M | -$11.54M |
| Capital expenditure | $23.00K | $86.00K | $0.00 | $115.00K | $179.00K | $15.00K |
| Investing cash flow | $77.26M | $100.06M | -$143.04M | -$13.29M | $8.86M | $10.87M |
| Dividends paid | - | - | - |
Viridian Therapeutics, Inc.DE reported operating cash flow of -$276.39M for fiscal year 2025. That is down 19.0% from -$232.32M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.76M (FY 2016) to -$276.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $6.36M | $9.21M | $177.08M | $8.20M | $738.00K | $1.26M |